Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1940 1
1944 1
1946 4
1947 2
1948 10
1949 4
1950 8
1951 7
1952 4
1953 7
1954 8
1955 6
1956 6
1957 6
1958 5
1959 6
1960 2
1961 12
1962 7
1963 5
1964 20
1965 7
1966 14
1967 17
1968 17
1969 24
1970 21
1971 14
1972 18
1973 17
1974 25
1975 24
1976 31
1977 21
1978 17
1979 21
1980 11
1981 12
1982 25
1983 25
1984 27
1985 32
1986 27
1987 27
1988 25
1989 37
1990 40
1991 42
1992 45
1993 35
1994 27
1995 38
1996 38
1997 45
1998 31
1999 39
2000 58
2001 62
2002 51
2003 46
2004 48
2005 51
2006 48
2007 51
2008 55
2009 59
2010 78
2011 70
2012 69
2013 70
2014 81
2015 95
2016 89
2017 93
2018 100
2019 85
2020 94
2021 133
2022 103
2023 102
2024 72

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,694 results

Results by year

Filters applied: . Clear all
Page 1
Cervical Cancer: An Overview of Pathophysiology and Management.
Johnson CA, James D, Marzan A, Armaos M. Johnson CA, et al. Among authors: james d. Semin Oncol Nurs. 2019 Apr;35(2):166-174. doi: 10.1016/j.soncn.2019.02.003. Epub 2019 Mar 14. Semin Oncol Nurs. 2019. PMID: 30878194 Review.
Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.
Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S. Gogola E, et al. Among authors: james di. Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008. Cancer Cell. 2018. PMID: 29894693 Free article.
Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.
Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S. Byrd JC, et al. Among authors: james df. N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. N Engl J Med. 2013. PMID: 23782158 Free PMC article. Clinical Trial.
Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, Simkovic M, Samoilova O, Novak J, Ben-Yehuda D, Strugov V, Gill D, Gribben JG, Hsu E, Lih CJ, Zhou C, Clow F, James DF, Styles L, Flinn IW. Moreno C, et al. Among authors: james df. Lancet Oncol. 2019 Jan;20(1):43-56. doi: 10.1016/S1470-2045(18)30788-5. Epub 2018 Dec 3. Lancet Oncol. 2019. PMID: 30522969 Clinical Trial.
Laser-Induced Graphene.
Ye R, James DK, Tour JM. Ye R, et al. Among authors: james dk. Acc Chem Res. 2018 Jul 17;51(7):1609-1620. doi: 10.1021/acs.accounts.8b00084. Epub 2018 Jun 20. Acc Chem Res. 2018. PMID: 29924584
Thirty sweet years of GLUT4.
Klip A, McGraw TE, James DE. Klip A, et al. Among authors: james de. J Biol Chem. 2019 Jul 26;294(30):11369-11381. doi: 10.1074/jbc.REV119.008351. Epub 2019 Jun 7. J Biol Chem. 2019. PMID: 31175156 Free PMC article. Review.
Waldenstrom's syndromes.
James DG. James DG. J Med Biogr. 2009 Aug;17(3):173. doi: 10.1258/jmb.2009.009023. J Med Biogr. 2009. PMID: 19723972 No abstract available.
Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2.
Nguyen T, Lau A, Bier J, Cooke KC, Lenthall H, Ruiz-Diaz S, Avery DT, Brigden H, Zahra D, Sewell WA, Droney L, Okada S, Asano T, Abolhassani H, Chavoshzadeh Z, Abraham RS, Rajapakse N, Klee EW, Church JA, Williams A, Wong M, Burkhart C, Uzel G, Croucher DR, James DE, Ma CS, Brink R, Tangye SG, Deenick EK. Nguyen T, et al. Among authors: james de. J Exp Med. 2023 Jun 5;220(6):e20221020. doi: 10.1084/jem.20221020. Epub 2023 Mar 21. J Exp Med. 2023. PMID: 36943234 Free PMC article.
2,694 results